2024
Psilocybin and other Psychedelics
Kaye A, Kelmendi B, Rivera M, Pittenger C. Psilocybin and other Psychedelics. 2024 DOI: 10.1016/b978-0-323-95702-1.00178-0.Peer-Reviewed Original ResearchPsychedelic drugsSerotonin 5-HT2A receptorsHuman neuroimaging studiesAlcohol use disorderPatterns of activityTransdiagnostic efficacyDepressive disorderPsychedelic agentsClassic psychedelicsNeuroimaging studiesMode networkUse disorderPsychedelic propertiesPsychotherapeutic supportAssociation cortexPsilocybinPsychological effectsPsychedelicsDifferential effectsHealing contextControlled Substances ActDisordersPotential therapeutic useControlled studiesSerotonin
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsion